The federal reclassification of cannabis from Schedule I to Schedule III was supposed to mark a turning point. For tax purposes and research access, it does. For the majority of cannabis businesses trying to open a bank account, accept a credit card, or secure a line of credit - not so much. The core problem hasn't moved: cannabis remains federally illegal, and that single fact is load-bearing for almost everything that follows in financial services.
The Gap Between Symbolic Reform and Financial Reality
Here's the catch with rescheduling as a policy tool: it reorganizes the federal drug classification system, but it doesn't amend the Bank Secrecy Act, the Controlled Substances Act's illegality provisions, or the anti-money laundering frameworks that financial institutions actually operate under. Banks aren't avoiding cannabis businesses because of where cannabis sits on a scheduling chart. They're avoiding them because accepting deposits from a federally illegal enterprise - regardless of state-level sanction - exposes them to asset forfeiture risk and regulatory scrutiny that most compliance officers won't touch.
Alan Brochstein, founder of New Cannabis Ventures and a long-standing analyst of the cannabis sector, put it plainly: "Just because you're Schedule III instead of Schedule I, you're still federally illegal." The reclassification, formalized through an April 23 order signed by acting attorney general Todd Blanche, formally acknowledges cannabis's medical applications. What it doesn't do is create a legal safe harbor for institutions that bank operators in those same state-licensed medical programs.
Visa and Mastercard have held their position against cannabis processing not because of scheduling semantics but because federal illegality creates liability exposure that card networks - operating across state lines and internationally - cannot compartmentalize. Rescheduling doesn't change that calculus.
A Two-Tier Industry Taking Shape
What's striking here is the growing divide between operators who have managed to secure banking access and those who haven't. Large, publicly traded multi-state operators - the MSOs that dominate headlines and investor decks - have resources to retain specialized compliance counsel, navigate state-chartered bank relationships, and absorb the cost of bespoke financial arrangements. Some have secured accounts; some process payments through workarounds that occupy a legally ambiguous middle ground.
Smaller operators don't have that runway. They function in cash-heavy environments: physical deposits, armored transport, on-site safes, and the elevated security risk that comes with all of it. That's not a minor inconvenience - it's a structural disadvantage that compounds over time, inflating operating costs and limiting access to the kind of working capital that allows a business to grow or weather a downturn.
Richard Ormond, a partner at Los Angeles-based law firm Buchalter, noted that financial institutions will likely remain cautious, particularly given that the bulk of cannabis revenue in major markets like California flows from recreational sales - a category that the reclassification doesn't legitimize at the federal level in any meaningful way. Medical rescheduling for a state that generates most of its cannabis tax revenue from adult-use retail is, to put it plainly, beside the point for financial access purposes.
The SAFER Banking Act and What Congress Could Actually Fix
The legislative fix with real potential is the SAFER Banking Act, first proposed in 2023 and still stalled. The bill would extend a statutory safe harbor to banks, credit unions, and other depository institutions that serve state-licensed cannabis businesses - shielding them from federal penalties, regulatory action, and asset forfeiture for doing so. That's the mechanism that would actually change behavior: not a scheduling reclassification, but a direct amendment to the legal risk equation that financial institutions face.
Congressional hearings on the SAFER Act are scheduled for June, which at minimum puts the legislation back in front of lawmakers with some momentum. Whether that translates into floor votes is another matter. The bill has bipartisan support in principle; the complications are procedural and, in part, reflect broader disagreements about federal drug policy that a banking bill alone can't resolve.
Until passage, the industry will keep operating around the edges - state-level credit unions in cannabis-friendly jurisdictions, fintech platforms built specifically for the sector, and cash management systems that exist nowhere else in retail. These workarounds function well enough for established operators; they are poor substitutes for standard commercial banking, and they do nothing to reduce the cost burden on smaller businesses.
What Rescheduling Does Change - and Why It Still Matters
None of this diminishes the genuine downstream effects of Schedule III status. Reclassification opens the door to federally funded research that was essentially barred under Schedule I. It reduces the tax burden imposed by Section 280E of the Internal Revenue Code - which had prevented cannabis businesses from deducting ordinary business expenses because they were trafficking a Schedule I substance - a provision that had functioned, in practice, as a punitive tax on legal operators. And it sends a signal of legitimacy to the 40-plus states running medical programs that federal policy is, slowly, aligning with medical and scientific consensus on cannabis's therapeutic applications.
These are real gains. They matter to operators, patients, and researchers. But they're largely upstream of the daily financial friction that defines the experience of running a cannabis business. The research access matters to pharmaceutical developers. The tax relief matters to the balance sheet. The bank account - the ability to pay employees by direct deposit, accept card payments at the register, or apply for a conventional small business loan - that remains out of reach for most of the industry, and rescheduling doesn't change the mechanism that keeps it that way.
What moves that needle, if anything does, is Congressional action. The June hearings are the next concrete moment worth watching.
